These findings in conjunction with the observed detrimental effects of ablated IL-1 signaling in IL-11/STAT3 mediated gastric pathology demonstrated here, suggest that IL-1 receptor blockade, or immunoneutralisation of ligands may not be suitable targets for preventing gastric cancer progression. This evidence concerns the gene IL11 and gastric cancer.